Internal Medicine
Extremely rare cases of Guillain-Barré reported with Johnson & Johnson vaccine for Covid-19.
13 Jul, 2021 | 09:48h | UTCJ&J’s Covid-19 vaccine may trigger neurological condition in rare cases, FDA says – STAT
See also: Johnson & Johnson Vaccine Is Linked To Neurological Disorder In Extremely Rare Cases – NPR AND F.D.A. Attaches Warning of Rare Nerve Syndrome to Johnson & Johnson Vaccine – The New York Times
Another RCT evaluating the efficacy and quality of life of antibiotic-only treatment of acute uncomplicated appendicitis.
13 Jul, 2021 | 09:33h | UTCA Randomized Clinical Trial Evaluating the Efficacy and Quality of Life of Antibiotic-only Treatment of Acute Uncomplicated Appendicitis: Results of the COMMA Trial – Annals of Surgery (link to abstract – $ for full-text)
Related: A Randomized trial comparing antibiotics with appendectomy for appendicitis AND Antibiotics alone for uncomplicated appendicitis: Oral Moxifloxacin almost as good as intravenous Ertapenem + oral Levofloxacin AND Observational study: 67.1% success rate with nonoperative management of children with uncomplicated appendicitis AND Randomized Trial: Quality of Life and Patient Satisfaction at 7-Year Follow-up of Antibiotic Therapy vs. Appendectomy for Uncomplicated Acute Appendicitis AND Meta-Analysis: Antibiotic Treatment vs. Appendectomy for Uncomplicated Acute Appendicitis in Adults and Children AND Nonoperative treatment for nonperforated appendicitis in children: a systematic review and meta-analysis – Pediatric Surgery International
Commentary on Twitter
The debate continues!
Another RCT comparing antibiotics to surgery for uncomplicated appendicitis – COMMA trial from 🇮🇪
Recurrence within 1-year : 25% after AB
Superior quality of life at 3 and 12mo after surgery.https://t.co/Yv51qpxchb
— Ville Sallinen (@villesallinen) July 11, 2021
2021 ACR Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.
13 Jul, 2021 | 09:41h | UTC
Podcast | An Antibiotics Primer.
13 Jul, 2021 | 09:35h | UTC#284 An Antibiotics Primer, with @IDdocAdi – The Curbsiders
2021 ACR Guideline for the Management of Polyarteritis Nodosa.
13 Jul, 2021 | 09:37h | UTC
M-A: Similar mortality with Fluoroquinolones or Macrolides for the treatment of Legionella Pneumonia.
13 Jul, 2021 | 09:18h | UTCAre Fluoroquinolones or Macrolides Better for Treating Legionella Pneumonia? A Systematic Review and Meta-analysis – Clinical Infectious Diseases (link to abstract – $ for full-text)
Review: Infectious disease-associated encephalopathies.
13 Jul, 2021 | 09:30h | UTCInfectious disease-associated encephalopathies – Critical Care
Commentary on Twitter
A Review published in Critical Care focuses on the pathophysiology of encephalopathies associated with sepsis, malaria, influenza, and COVID-19; emerging therapeutic strategies; and the role of neuroinflammation. https://t.co/991S4kAKJk
— BMC (@BioMedCentral) July 11, 2021
M-A: Global prevalence of functional constipation according to the Rome criteria.
13 Jul, 2021 | 09:17h | UTC
Commentary on Twitter
New research – Barberio et al – Global prevalence of functional constipation according to the Rome criteria: a systematic review and meta-analysishttps://t.co/pqkXltWnYU#constipation #gitwitter @bribarberio @DrCJudge @EdoardoSavarino @alex_ford12399 pic.twitter.com/NUnZgaVS46
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) June 4, 2021
RCT: Comparison of nebulized ketamine at three different dosing regimens for treating painful conditions in the emergency department.
13 Jul, 2021 | 09:22h | UTCComparison of Nebulized Ketamine at Three Different Dosing Regimens for Treating Painful Conditions in the Emergency Department: A Prospective, Randomized, Double-Blind Clinical Trial – Annals of Emergency Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Nebulized Ketamine for pain in the ED? No way…Well- here you go-Comparison of Nebulized Ketamine at Three Different Dosing Regimens for Treating Painful Conditions in the ED. https://t.co/v3UT0Y0LdU #FOAMed #FOAMems #FOAMtox #FOAMcc #FOAMpharm
— Sergey Motov (@painfreeED) July 3, 2021
[Preprint] Heparin for Moderately Ill Patients with Covid-19 – “In moderately ill ward patients with Covid-19 and elevated D-dimer level, therapeutic heparin did not significantly reduce the primary outcome but decreased the odds of death at 28 days”.
12 Jul, 2021 | 03:14h | UTCHeparin for Moderately Ill Patients with Covid-19 – medRxiv
Related: RCT: In patients hospitalized with Covid-19 with elevated D-Dimer, a full-dose anticoagulation strategy based on rivaroxaban (full-dose heparins in unstable patients) + rivaroxaban to day 30 was not better than prophylactic anticoagulation and increased bleeding risk. AND [Preprint] Practice Changing RCT: Therapeutic-dose anticoagulation with heparin (LMWH or unfractionated heparin) improves outcomes in non-critically ill patients with Covid-19 – the superiority of therapeutic-dose anticoagulation was seen in both high and low D-dimer groups. AND [Preprint] RCT: Full-dose/therapeutic anticoagulation provides no benefit in critically ill patients with Covid-19
Commentary on Twitter (thread – click for more)
🚨Final results of the RAPID trial now pub'd @medrxivpreprint 🚨 RAPID was an open-label trial that randomly assigned hospitalized ward patients with COVID-19 and elevated D-dimer levels to therapeutic or prophylactic heparin. 🧵 1/10 https://t.co/oxiyXQAPeK pic.twitter.com/V2GtruEyM2
— Michelle Sholzberg (@sholzberg) July 9, 2021
RCT: Another study shows Azithromycin does not improve outcomes in patients with Covid-19.
12 Jul, 2021 | 03:09h | UTCCommentaries: Trial shows that the antibiotic azithromycin does not prevent mild COVID cases progressing to hospitalization, death – European Society of Clinical Microbiology and Infectious Diseases AND Azithromycin: can its benefit be ruled out in mild COVID-19? – The Lancet Respiratory Medicine
Related: M-A: Azithromycin does not reduce the need for invasive mechanical ventilation or mortality in patients with Covid-19. AND RCT: Azithromycin provides no benefit for community treatment of patients with suspected COVID-19 AND RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19 AND [Press release – not published yet] Azithromycin and doxycycline are not generally effective against COVID-19 in patients treated at home, shows PRINCIPLE trial AND Coalition Covid-19 Brazil – Randomized trial: Azithromycin not beneficial for patients admitted to the hospital with severe Covid-19 AND Coalition Covid-19 Brazil – Randomized trial: hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19
Commentary on Twitter
In patients with mild-to-mod #COVID19 managed without hospital admission, azithromycin + SOC did not reduce the risk of subsequent hospital admission or death
Read the ATOMIC2 trial here https://t.co/QXJ7T08JZS, being presented at #ECCMID2021 by lead author Tim Hinks @HinksLab pic.twitter.com/ZDiPhuQqFB
— The Lancet Respiratory Medicine (@LancetRespirMed) July 9, 2021
A correlate of protection for SARS-CoV-2 vaccines is urgently needed – “Recent studies suggest that neutralizing antibodies could serve as a correlate of protection for vaccines against SARS-CoV-2 in humans”.
12 Jul, 2021 | 03:03h | UTCA correlate of protection for SARS-CoV-2 vaccines is urgently needed – Nature Medicine
Pfizer says it’s time for a Covid booster; FDA and CDC say not so fast.
12 Jul, 2021 | 03:08h | UTCPfizer says it’s time for a Covid booster; FDA and CDC say not so fast – CNN
See also: CDC, FDA contradict Pfizer on COVID-19 vaccine booster – CIDRAP AND Do I need a COVID-19 booster shot? 6 questions answered on how to stay protected – The Conversation AND Pfizer suggests booster shots will be needed this year, but government officials say science will dictate the timing – The Washington Post AND Pfizer to seek OK for 3rd vaccine dose; shots still protect – Associated Press AND Citing the Delta Variant, Pfizer Will Pursue Booster Shots and a New Vaccine – The New York Times (a few articles per month are free) AND Question open on need for COVID booster shot, data awaited, WHO says – Reuters
Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report.
12 Jul, 2021 | 01:41h | UTC
Ranitidine absolved? FDA study finds Ranitidine does not convert to carcinogen NDMA, regardless of diet.
12 Jul, 2021 | 01:36h | UTCEditorial: Ranitidine and Risk of N-Nitrosodimethylamine (NDMA) Formation
Commentary: Ranitidine: FDA finds no evidence of elevated NDMA, regardless of diet
Commentaries on Twitter
Despite ranitidine (zantac) being pulled from market last year, a new study from the FDA did not find evidence that it increases concentrations of the carcinogenic metabolite people were worried about (i.e., it's probably safe). From @JAMA_current https://t.co/AdRic2GdXS
— Zack Williams, PhD (@QuantPsychiatry) June 28, 2021
In this crossover, randomized clinical trial, oral ranitidine did not significantly increase 24-hour urinary excretion of NDMA when administered with a noncured-meats diet or a cured-meats diet. https://t.co/EszRvfJOFJ
— JAMA (@JAMA_current) June 28, 2021
AHA Scientific Statement: Assessing and Addressing Cardiovascular Health in People Who Are Transgender and Gender Diverse.
12 Jul, 2021 | 01:43h | UTCNews release: Discrimination, stress linked to poorer heart health in transgender, gender diverse adults – American Heart Association
Clinical Practice Guideline for Postoperative Rehabilitation in Older Patients With Hip Fractures.
12 Jul, 2021 | 01:39h | UTCRelated: Guideline for the perioperative management of hip fractures 2020
Review: Lipoprotein(a) and cardiovascular diseases.
12 Jul, 2021 | 01:33h | UTCLipoprotein(a) and Cardiovascular Diseases – JAMA (free for a limited period)
RCT: Another study shows that non-antibiotic outpatient treatment in mild acute diverticulitis is safe.
12 Jul, 2021 | 01:29h | UTCEfficacy and Safety of Non-Antibiotic Outpatient Treatment in Mild Acute Diverticulitis (DINAMO-study): A Multicentre, Randomised, Open-Label, Non-Inferiority Trial – Annals of Surgery (link to abstract – $ for full-text)
Related: State of the Art Review: Management of colonic diverticulitis AND Treatment of Uncomplicated Acute Diverticulitis Without Antibiotics: A Systematic Review and Meta-analysis – Diseases of the Colon & Rectum AND Antibiotics Do Not Reduce Length of Hospital Stay for Uncomplicated Diverticulitis in a Pragmatic Double-Blind Randomized Trial – Clinical Gastroenterology and Hepatology AND Randomized Trial: Antibiotic Avoidance Associated with Similar Long-term Outcomes in Uncomplicated Diverticulitis
Commentary on Twitter
Another (final?) nail in the coffin for antibiotics in uncomplicated diverticulitis? DINAMO study from Spain – Outpatient treatment with antibiotics versus symptomatic Tx.
No difference in hospitalization rate or revisits to ER.https://t.co/wOc3tBGfxr @AnnalsofSurgery
— Ville Sallinen (@villesallinen) July 9, 2021
RCT: CoronaVac showed efficacy of 83.5% for preventing symptomatic SARS-CoV-2 infection.
9 Jul, 2021 | 10:22h | UTCInvited commentary: CoronaVac: more data for regulators and policy makers
Commentary on Twitter
NEW—Interim analysis from phase 3 trial suggests efficacy of 2 doses of #CoronaVac is 83.5% against symptomatic #COVID19. More research is needed to confirm efficacy in the long term, in a more diverse group, and against emerging #variants of concern.
🔗 https://t.co/TN5b6wwclc pic.twitter.com/4zOvJFIIOH
— The Lancet (@TheLancet) July 8, 2021
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
9 Jul, 2021 | 10:16h | UTCReduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization – Nature
Commentaries: Study highlights need for full Covid vaccination to protect against Delta variant – STAT AND How does the Delta variant dodge the immune system? Scientists find clues. – The New York Times
Commentary on Twitter (thread – click for more)
Just published @Nature
Delta variant protection by mRNA and AZ vaccines requires 2-doses, little neutralizing antibody (nAb) with 1-dose, and insufficient nAb with prior covidhttps://t.co/TOgJdMe0g6 pic.twitter.com/KWLb9rBZ44— Eric Topol (@EricTopol) July 8, 2021
CDC: Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients – “Continued use of mRNA COVID-19 vaccines in all recommended age groups will prevent morbidity and mortality from COVID-19 that far exceed the number of cases of myocarditis expected”.
9 Jul, 2021 | 10:17h | UTC
Commentary on Twitter
In a new @CDCMMWR, the Advisory Committee on Immunization Practices recommends everyone 12 & older get a #COVID19 vaccine. The benefits of vaccination in preventing illness & death outweigh the rare risk of heart inflammation after vaccination. More: https://t.co/iPjbhU5jeV. pic.twitter.com/IggrZ4DX7L
— CDC (@CDCgov) July 6, 2021
After the pandemic: perspectives on the future trajectory of COVID-19.
9 Jul, 2021 | 10:18h | UTCAfter the pandemic: perspectives on the future trajectory of COVID-19 – Nature
Will COVID become a disease of the young? – “A growing share of infections among unvaccinated youths in countries with high vaccination rates is putting the spotlight on the role of young people in the pandemic”.
9 Jul, 2021 | 10:14h | UTCWill COVID become a disease of the young? – Nature
2021 ACR Guideline for the Management of ANCA–Associated Vasculitis.
9 Jul, 2021 | 10:09h | UTC